

Topographically Based Search for an “Ethogram” Among a Series of Novel D₄ Dopamine Receptor Agonists and Antagonists

Jeremiah J. Clifford, Ph.D., and John L. Waddington, Ph.D., D.Sc.

The effects of three selective D₄ antagonists [CP-293,019, L-745,870, and Ro 61-6270] and two putative selective D₄ agonists [CP-226,269 and PD 168077] were compared with those of the generic D₂-like [D_{2L/S}, D₃, D₄] antagonist haloperidol to identify any characteristic “ethogram,” in terms of individual topographies of behavior within the natural rodent repertoire, as evaluated using ethologically based approaches. Among the D₄ antagonists, neither L-745,870 (0.0016–1.0 mg/kg) nor Ro 61-6270 (0.2–25.0 mg/kg) influenced any behavior; whereas, CP-293,019 (0.2–25.0 mg/kg) induced episodes of nonstereotyped sniffing, sifting, and vacuous chewing; there were no consistent effects on responsivity to the D₂-like agonist RU 24213. Among the putative D₄ agonists, CP-226,269 (0.2–

25.0 mg/kg) failed to influence any behavior; whereas, PD 168077 (0.2–25.0 mg/kg) induced nonstereotyped shuffling locomotion with uncoordinated movements, jerking, and yawning, which were insensitive to antagonism by CP-293,019, L-745,870, or haloperidol. These findings fail to indicate any “ethogram” for selective manipulation of D₄ receptor function at the level of the interaction between motoric and psychological processes in sculpting behavioral topography over habituation of exploration through to quiescence and focus attention on social, cognitive, or other levels of examination.

[Neuropsychopharmacology 22:538–544, 2000]

© 2000 American College of Neuropsychopharmacology.

Published by Elsevier Science Inc.

KEY WORDS: D₄ dopamine receptor; Behavioral topography; D₄ antagonists; CP-293,019; L-745,870; Ro 61-6270; D₄ agonists; CP-226,269; PD 168077; Ethological assessment

Although identification of D₁ and D₂ dopamine (DA) receptor subtypes evolved from classical functional/pharmacological considerations, which included otherwise anomalous DAergic behavioral effects, members of the broader D₁-like [D_{1A} /D₁, D_{1B}/D₅] and D₂-like [D_{2L/S}, D₃, D₄] families of receptors have been identified through molecular biology and characterized primarily in terms of their neuroanatomical localization and cel-

lular neurobiology (Missale et al. 1998; Neve and Neve 1997; Waddington et al. 1995, 1998). In particular, any behavioral role for the D₄ receptor (Van Tol et al. 1991) remains poorly understood, primarily because of a paucity of agonists and antagonists showing meaningful selectivity for this site (Tarazi and Baldessarini 1999). It is on this background that interest in the D₄ receptor as a target for antipsychotic therapy evolved indirectly from: (1) its extrastriatal, primarily corticolimbic localization; (2) the discovery that clozapine, an efficacious antipsychotic drug with a very low propensity to induce extrapyramidal side effects, evidenced some modest preference for D₄ over D₂ receptors; and (3) controversial evidence that D₄ receptor density was elevated in schizophrenia (Seeman et al. 1997; Tarazi and Baldessarini 1999); strikingly, this interest evolved in the absence of any substantive body of preclinical evidence for D₄ receptor involvement in behavioral models of antipsychotic activity.

From the Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, Ireland.

Address correspondence to: John L. Waddington, Ph.D., D.Sc., Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin 2, Ireland.

Received August 4, 1999; revised October 18, 1999; accepted November 1, 1999.

Subsequently, a series of selective D₄ antagonists has been identified. Among these, CP-293,019 (Mansbach et al. 1998; Sanner et al. 1998), L-745,870 (Bristow et al. 1997; Patel et al. 1997), NGD 94-1 (Tallman 1998), PNU-101387 (Merchant et al. 1996), Ro 61-6270 (Hartman et al. 1996), and S 18126 (Millan et al. 1998) have received, to date, the more extensive preclinical evaluation, and there is some consensus that they show little or no activity in traditional models of either antipsychotic activity (e.g., DA agonist-induced responsivity and inhibition of conditioned avoidance responding) or of extrapyramidal side effect liability (e.g., induction of catalepsy); there are only limited and, thus far, contradictory data as to whether they seem to be inactive (Bristow et al. 1997), partially active (Tallman 1998), or active (Mansbach et al. 1998) in such newer models as restoration of DA agonist-induced disruption of prepulse inhibition.

Although little or no effect of selective D₄ antagonists on spontaneous behavior has been noted, this has almost invariably involved assessment in terms of photobeam interruptions, which fail to resolve other than the most elementary components of otherwise composed behavior. Regarding selective D₃ antagonists, we have demonstrated recently (Clifford and Waddington 1998) that evaluation of behavioral topography in rodents using an ethologically based approach (Colgan 1978) can identify drug profiles ("ethograms") that can clearly distinguish between agents seemingly of the same pharmacological class. Furthermore, we recently described (Clifford et al. 1998) how this approach (Gérald and Clayton 1999) can reveal interactions at the level of individual behaviors between receptor manipulation and such psychological processes as habituation, which sculpts behavioral topography, in a manner that cannot be accessed in detail by photobeam approaches.

Given that studies to date on any behavioral role for D₄ receptors have emerged primarily in the context of antipsychotic potential, even so fundamental a question as the extent to which they might play any role in regulating behavior has received little attention. Therefore, we examined three selective D₄ antagonists (CP-293,019, L-745,870, and Ro 61-6270; Table 1), as compared to the reference D₂-like [D_{2L/S}, D₃, D₄] antagonist haloperidol, to identify any associated "ethogram" and have studied in the same manner any effects on behavioral responsivity to the reference D₂-like [D_{2L/S}, D₃, D₄] agonist RU 24213 (Euvrard et al. 1980; Waddington et al. 1995; Waddington and O'Boyle 1989). Very recently, two putative selective D₄ agonists, CP-226,269 and PD 168077 (Glase et al. 1997; Zorn et al. 1997; Table 1) have been described, but their psychopharmacological profiles remain essentially unexplored; we have studied these agents similarly, to probe for any "ethogram" complementary to that for selective D₄ antagonists.

Table 1. D₄ Agonists and Antagonists and Their Selectivities Within the D₂-line [D₂, D₃, D₄] Family of Receptors

	Affinity [K _i , nM]			
	D ₂	D ₃	D ₄	D ₂ /D ₄
Antagonists				
CP-293,019 ^a	>3310	>2000	3.4	>1000
L-745,870 ^b	960	2300	0.4	>2200
Ro 61-6270 ^c	>5000	>5000	5.0	>1000
Agonists				
CP-226,269 ^d	>600	NA	6.0	>100
PD 168077 ^e	3740	2810	9.0	>415

NA, not available.

^aSanner et al. (1998).

^bPatel et al. (1997).

^cHartman et al. (1996).

^dZorn et al. (1997).

^eGlase et al. (1997).

METHODS

Behavioral Studies

Young adult male Sprague-Dawley rats (180–350 g; Beaumont Hospital, Dublin) were housed in groups of five per cage with food and water available ad libitum, and were maintained at 21 ± 1°C on a 12/12 h (0900 on; 2100 off) light/dark regimen. On experimental days, they were placed individually in clear glass observation cages (36 × 20 × 20 cm) and either received drug or vehicle immediately (nonhabituated condition; exploring-habituating to a novel environment;) or were left undisturbed for a habituation period of 3 h (habituated condition) before assessment.

Behavioral assessments were carried out in a manner similar to that described previously (Clifford et al. 1998; Clifford and Waddington 1998; Deveney and Waddington 1996, 1997). Following injection of drug or vehicle, animals were assessed using a rapid time-sampling behavioral checklist technique. For this procedure, each rat was observed individually for 5-s periods at 1-min intervals over 15 consecutive minutes, using an extended, ethologically based behavioral checklist. This made possible the determination of the presence or absence of the following individual behaviors (occurring alone or in any combination) in each 5-s period: stillness (motionless, with no behavior evident); sniffing (flaring of nostrils with movements of vibrissae); locomotion (coordinated movement of all four legs resulting in change of location); rearing (of any form); rearing free (front paws raised off floor with motion upward or outward away from any surface); rearing to wall (front paws raised off floor with motion upward or outward toward cage wall); rearing seated (front paws raised off floor from a seated position); sifting (characteristic pattern of coordinated movements of the forepaws through bedding material on cage floor); grooming (of

any form); intense grooming (characteristic pattern of grooming of the snout and then face with the forepaws, followed by vigorous grooming of the hind flank or anogenital region with the snout); vacuous chewing (not directed onto any physical material); chewing (directed onto any physical material without consumption); eating (chewing with consumption); and licking. After this 15-min assessment using the behavioral checklist, animals were evaluated using a conventional 0- to 6-point stereotypy scale: 0 = asleep or inactive; 1 = episodes of normal activities; 2 = discontinuous activity with bursts of prominent sniffing or rearing; 3 = continuous stereotyped activity such as sniffing or rearing along a fixed path; 4 = stereotyped sniffing or rearing fixated in one location; 5 = stereotyped behavior with bursts of licking or gnawing; 6 = continuous licking or gnawing. This cycle of assessment by behavioral checklist followed by stereotypy scale was repeated on two further occasions over a total observation period of 1 h; some studies were continued into additional periods thereafter. For studies in the nonhabituated condition, rats were used on a single occasion only; otherwise, they were used on two occasions only with exposure only to a single drug, separated by a drug-free interval of at least 1 week, with random allocation to one of the various dosages in each instance. All assessments were made by a single observer unaware of the treatment given to each animal. These studies were approved by the Research Committee of the Royal College of Surgeons in Ireland and were conducted under license from the Department of Health in accordance with Irish legislation and EU regulations for the care and use of experimental animals.

Drugs

The following selective D₄ antagonists were used: CP-293,019 [(7R,9aS)-7-(4-fluorophenoxy)methyl-2-(5-fluoropyrimidin-2-yl)-2,3,4,6,7,8,9,9a-octahydro-1H-pyridol](1,2-a)pyrazine; Pfizer, USA]; L-745,870 [3-[4-(4-chlorophenyl)piperazin-1-yl]methyl-1H-pyrrolo[2,3-b]pyridine; Merck Sharpe & Dohme, UK]; Ro 61-6270 [2-amino-benzoic acid-1-benzyl-piperidin-4-yl-ester; Roche, Switzerland]. The following putative selective D₄ agonists were used: CP-226, 269 [5-fluoro-2-(4-pyridin-2-yl-piperazin-1-methyl)-1H-indole; Pfizer, USA]; PD 168077 [N-[methyl-4-(2-cyanophenyl)piperazinyl-3-methylbenzamide] Parke-Davis, USA].

CP-293,019 was dissolved in 40% cyclodextrin (RBI, USA) and injected in a volume of 6 ml/kg; L-745,870 was dissolved in a minimum of 0.1N hydrochloric acid, made up to volume with distilled water and injected in a volume of 2 ml/kg; Ro 61-6270 was dissolved in distilled water and injected in a volume of 2 ml/kg; CP-226,269 was dissolved in 40% dimethylsulphoxide and injected in a volume of 2 ml/kg; PD 168077 was dis-

solved using ultrasonication in a minimum of glacial acetic acid made up to volume with 40% cyclodextrin and injected in a volume of 4 ml/kg. RU 24213 (Hoechst-Marion-Roussel, France) was dissolved in distilled water and injected in a volume of 2 ml/kg; haloperidol (RBI, USA) was dissolved in a minimum of glacial acetic acid, made up to volume with distilled water and injected in a volume of 2 ml/kg. All drugs or their vehicles were injected subcutaneously into the flank, with antagonists or their vehicles given 30 min before agonists in combination experiments.

Data Analysis

From application of the behavioral checklist, the total "counts" for each individual behavior were determined as the number of 5-s observation windows in which a given behavior was evident, summed over a 1-h period, and expressed as means \pm SEM; stereotypy scores were averaged over the 1-h period and expressed similarly. These data were then analyzed using analysis of variance (ANOVA) or the Kruskal-Wallis nonparametric ANOVA, followed by Student's *t*-test or Mann-Whitney U-test.

RESULTS

D₄ Antagonist Effects on Behavior Over Nonhabituated (Exploratory) Condition

Haloperidol (0.004–0.5 mg/kg) dose dependently reduced sniffing ($p < .01$), locomotion ($p < .05$), rearing ($p < .001$), grooming ($p < .01$), and chewing ($p < .01$), with no significant effect on any other topography of behavior over a 1-h period; no additional effects were evident when observations were continued over a second, consecutive 1-h period. Neither CP-293,019 (0.2–25.0 mg/kg), L-745,870 (0.008–1.0 mg/kg) nor Ro 61-6270 (0.2–25.0 mg/kg) significantly influenced any topography of behavior over a 1-h period; no significant effects were evident when observations were continued over a second, consecutive 1-h period.

D₄ Antagonist Effects on Behavior Over Habituated Condition

Haloperidol (0.0008–0.1 mg/kg) dose dependently reduced intense grooming ($p < .01$) but failed to influence significantly any other topography of behavior over a 1-hr period; no additional effects were evident when observations were continued over a second, consecutive 1-h period. CP-293,019 (0.2–25.0 mg/kg) dose-dependently induced sniffing ($p < .001$) and vacuous chewing ($p < .01$), with some induction of sifting ($p < .05$), whereas grooming ($p < .001$) and episodes of stillness ($p < .001$) were reduced over the 1-h period; increases

in stereotypy score were confined to the range of 0–1, indicating that behavioral stimulation was occurring episodically in a nonstereotyped manner; no additional effects were evident when observations were continued over a second, consecutive 1-h period. Neither L-745,870 (0.0016–1.0 mg/kg) nor Ro 61-6270 (0.2–25.0 mg/kg) influenced significantly any topography of behavior over the 1-h period; no significant effects were evident when observations were continued over a second, consecutive 1-h period.

D₄ Antagonist Effects on D₂-Like Agonist-Induced Behavior Over Habituated Condition

RU 24213 (0.1–12.5 mg/kg) dose-dependently induced sniffing ($p < .001$), locomotion ($p < .001$), sifting ($p < .001$), and chewing ($p < .001$) with some yawning ($p < .05$); increases in stereotypy score ($p < .001$) in the range of 2–3 indicated threshold levels in terms of sniffing and locomotion, in the absence of compulsive licking or gnawing. An intermediate dose of 2.5 mg/kg RU 24213 was selected for D₄ antagonist studies to allow detection of either attenuation or potentiation of responsiveness. Following challenge with RU 24213 (2.5 mg/kg), sniffing ($p < .001$), locomotion ($p < .001$), rearing ($p < .001$) and chewing ($p < .01$) were dose-dependently blocked by pretreatment with haloperidol (0.02–0.5 mg/kg). CP-293,019 (0.2–25.0 mg/kg) failed to influence significantly any aspect of response topography; L-745,870 (0.04–1.0 mg/kg) antagonized only rearing ($p < .05$), although with an inverse dose dependency, and potentiated sifting ($p < .01$); Ro 61-6270 (0.2–25.0 mg/kg) antagonized only sniffing ($p < .01$), and potentiated episodes of stillness ($p < .01$); the baseline level of grooming ($p < .05$) was reduced by this drug combination. There were no significant effects on any other topography of responsiveness to RU 24213 or on stereotypy scores.

D₄ Agonist Effects on Behavior Over Habituated Condition

CP-226,269 (0.2–25.0 mg/kg) failed to influence significantly any topography of behavior over the 1-h period; no significant effects were evident when observations were continued over a second, consecutive 1-h period. PD 168077 (0.2–25.0 mg/kg) dose-dependently induced locomotion ($p < .01$), which took an unusual and characteristic “shuffling” form with uncoordinated movements together with yawning, and episodes of myoclonic jerking; grooming ($p < .01$), and rearing ($p < .05$) were reduced. Increases in stereotypy score were confined to the range of 0–1, indicating that behavioral stimulation was occurring episodically in a nonstereotyped manner. No additional effects were seen when observations were continued over a second, consecutive 1-h period.

D₄ Antagonist Effects on D₄ Agonist-Induced Behavior Over Habituated Condition

Following challenge with PD 168077 (25.0 mg/kg), haloperidol (0.004–0.1 mg/kg) antagonized only sniffing, whereas the baseline level of grooming was reduced by this drug combination; there were no significant effects of haloperidol on any other topography of responsiveness to PD 168077. CP-293,019 (0.2–25.0 mg/kg) and L-745,870 (0.04–1.0 mg/kg) failed to influence significantly any topography of responsiveness to PD 168077 (Figure 1).

DISCUSSION

CP-293,019, L-745,870, and Ro 61-6270 are novel D₄ antagonists showing >1000-fold selectivity over other members of the D₂-like receptor family and over their D₁-like counterparts; furthermore, they show >300-fold selectivity over numerous non-DAergic receptors, other than a >50-fold selectivity of CP-293,019 over 5-HT_{1A} and 5-HT_{2A} receptors (Sanner et al. 1998; Patel et al. 1997; Hartman et al. 1996). No characteristic “ethogram” for these D₄ antagonists was apparent, using dosage ranges shown to exert biological activity in the brain at alternative levels of examination (Hartman et al. 1996; Holland et al. 1996; Patel et al. 1997). Although CP-293,019 induced episodes of nonstereotyped sniffing, vacuous chewing, and sifting, with attenuation of grooming, no such profile was apparent for L-745,870 or Ro 61-6270; hence, these effects of CP-293,019 are unlikely to have a basis in D₄ antagonism. Similarly, these selective D₄ antagonists as a class failed to evidence any characteristic “ethogram” at the level of responsiveness to D₂-like [D_{2L/S}, D₃, D₄] receptor stimulation.

CP-226,269 and PD 168077 are the first agents to be identified as putative selective D₄ agonists. They show >100-fold selectivity over other members of the D₂-like receptor family and over their D₁-like counterparts; in addition, CP-226,269 shows an 80-fold selectivity over α_2 and >100-fold selectivity over several other non-DAergic receptors, whereas PD168077 shows a 20-fold selectivity over α_1 , and α_2 , a 45-fold selectivity over 5-HT_{1A}, and a 460-fold selectivity over 5-HT_{2A} receptors; each agent evidences intrinsic activity at the D₄ receptor in terms of quinpirole-like inhibition of forskolin-stimulated cAMP accumulation (Zorn et al. 1997) or stimulation of [³H]thymidine uptake (Glase et al. 1997) in CHO cells expressing the human D₄ receptor. However, to our knowledge, their psychopharmacological effects have yet to be studied. No “ethogram” for CP-226,269 was apparent over a wide dose range. Conversely, PD 168077 induced nonstereotyped episodes of a “shuffling” form of locomotion with uncoordinated movements, together with yawning and episodes of myoclonic jerking, in the course of which grooming and




Figure 1. Topographical responsivity to 25.0 mg/kg PD 168077 following pretreatment with 0.004–0.1 mg/kg haloperidol, 0.2–25.0 mg/kg CP-293,019, 0.04–1.0 mg/kg L-745,870 or vehicle over an initial 1-h period. Data are mean counts for each behavior indicated \pm SEM of $n = 8$ –32 animals per group. ^a $p < .05$, ^b $p < .01$, ^c $p < .001$ vs. vehicle (V); * $p < .05$, ** $p < .01$ *** $p < .001$ vs. PD 168077.

rearing were reduced. However, these responses to PD 168077 were insensitive to D₄ antagonism, either by CP-293,019 or by L-745,870; furthermore, they were insensitive to haloperidol. Therefore, it seems that these effects of PD 168077 are not just unrelated to D₄ receptor activation; rather, they seem to have a non-DAergic basis, the nature of which remains to be specified. This conclusion indicates caution in the use of PD 168077 to probe the functional role of D₄ receptors.

In the rat, D₄ receptors are located primarily in corticolimbic areas, particularly in frontal cortex, thalamus, and hypothalamus, with low levels in the striatum/nucleus accumbens (Jaber et al. 1996; Tarazi and Baldessarini 1999). It is, therefore, important to establish the extent to which the low level of D₄ receptors in the striatum/nucleus accumbens (or, indeed, the higher levels elsewhere) might influence the topography of spontaneous behavior under diverse conditions or of D₂-like agonist-induced behavior; it seems that on the basis of studies using selective D₄ agonists and antagonists, they have little role in this regard. Although a recent study in mice with targeted gene deletion ("knockout") of the D₄ receptor has indicated modest reductions in horizontal and vertical movements relative to wild types in terms of photobeam interruptions and heightened responsivity to methamphetamine (Rubinstein et al. 1997), no study with any D₄ antagonist has suggested a comparable profile.

In relation to any antipsychotic potential of selective D₄ antagonists, recent studies in mice with targeted gene deletion of individual members of the D₂-like receptor family indicate amphetamine-induced disruption of prepulse inhibition to be essentially a D₂ rather than a D₃ or D₄ receptor-mediated effect (Ralph et al. 1999). Selective D₄ antagonists appear not to influence phencyclidine-induced stereotyped behavior or social isolation (Sams-Dodd 1998), although they may reverse phencyclidine-induced cognitive deficits (Jentsch et al. 1999). The clozapine cue in drug discrimination responding does not seem to generalize to a selective D₄ antagonist (Goudie et al. 1998). In the only controlled clinical trial of a selective D₄ antagonist in schizophrenia to date, L-745,870 failed to evidence either antipsychotic activity or extrapyramidal effects (Kramer et al. 1997); the D₄/5-HT_{2A} antagonist fananserin (Heuillet et al. 1996) has also been shown recently to evidence such a lack of therapeutic efficacy, although there seemed to be some worsening of akathisia (Truffinet et al. 1999). Although the present lack of psychopharmacological signature for selective D₄ antagonists is complementary to their apparent inactivity both in models of antipsychotic activity and in the clinic, it remains to be clarified whether any agent with antipsychotic activity could be ethologically "silent." Furthermore, the present findings in no way preclude any functional role(s) for the D₄ receptor in social, cognitive, or other processes, which require further study.

ACKNOWLEDGMENTS

These studies were supported by the Research Committee of the Royal College of Surgeons in Ireland and the Higher Education Authority. We thank Hoechst-Marion-Roussel, Merck Sharpe & Dohme, Parke-Davis, Pfizer and Roche for kindly making drugs available to us.

REFERENCES

- Bristow LJ, Collinson N, Cook GP, Curtis N, Freedman SB, Kulagowski JJ, Leeson PD, Patel S, Ragan CI, Ridgill M, Saywell KL, Tricklebank MD (1997): L-745,870, a subtype selective dopamine D₄ receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests. *J Pharmacol Exp Ther* 283:1256–1263
- Clifford JJ, Waddington JL (1998): Heterogeneity of behavioral profile between three new putative selective D₃ dopamine receptor antagonists using an ethologically based approach. *Psychopharmacology* 136:284–290
- Clifford JJ, Tighe O, Croke DT, Drago J, Sibley DR, Waddington JL (1998): Topographical evaluation of the phenotype of spontaneous behavior in mice with targeted gene deletion of the D_{1A} dopamine receptor: Paradoxical elevation of grooming syntax. *Neuropharmacology* 37:1595–1602
- Colgan PW (1978): *Quantitative Ethology*. New York, Wiley
- Deveney AM, Waddington JL (1996): Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioral responses to the selective "D₁-like" dopamine receptor agonist A 68930 and selective "D₂-like" agonist RU 24213. *Psychopharmacology* 124:40–49
- Deveney AM, Waddington JL (1997): Psychopharmacological distinction between novel full efficacy "D₁-like" dopamine receptor agonists. *Pharmacol Biochem Behav* 58:551–558
- Euvrard C, Ferland L, Di Paulo T, Beaulieu M, Labrie F, Oberlander C, Raynaud JP, Boissier JR (1980): Activity of two new potent dopaminergic agonists at the striatal and anterior pituitary levels. *Neuropharmacology* 19:379–386
- Gerlai R, Clayton NS (1999): Analyzing hippocampal function in transgenic mice: An ethological perspective. *Trends Neurosci* 22: 47–51
- Glase SA, Akunne HC, Georgic LM, Heffner TG, MacKenzie RG, Manley PJ, Pugsley TA, Wise LD (1997): Substituted [(4-phenylpiperazinyl)-methyl]benzamides: Selective dopamine D₄ agonists. *J Med Chem* 40:1771–1772
- Goudie AJ, Smith JA, Taylor A, Taylor MAI, Tricklebank MD (1998): Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: Tests with subtype selective receptor ligands. *Behav Pharmacol* 9:699–710
- Hartman DS, Smeyne R, Zenner M-T, Goepfert C, Schlaeger E-I, Jenck F, Civelli O, Godel T, Riemer C (1996): RO 61-6270, a new highly selective dopamine D₄ receptor antagonist induces c-fos expression in mouse cortex. *Soc Neurosci Abstr* 22: 498
- Heuillet E, Petitot F, Mignani S, Malleron J-L, Lavayre J, Neliat G, Doble A, Blanchard J-C (1996): The naphthosul-

- tam derivative RP 62203 (fananserin) has high affinity for the dopamine D₄ receptor. *Eur J Pharmacol* 314:229–233
- Holland JP, Costello DG, de Wett JR, Rollema H, Sanner MA, Zorn SH, Seeger TF (1996): CP-293,019: A D₄ selective dopamine antagonist produces clozapine-like effects on c-fos mRNA and dopamine levels in rat brain. *Soc Neurosci Abstr* 22:1771
- Jaber M, Robinson SW, Missale C, Caron MG (1996): Dopamine receptors and brain function. *Neuropharmacology* 35:1503–1519
- Jentsch JD, Taylor JR, Redmond DE, Elsworth JD, Youngren KD, Roth RH (1999): Dopamine D₄ receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. *Psychopharmacology* 142:78–84
- Kramer MS, Last B, Getson A, Reines SA, and the D₄ dopamine antagonist group (1997): The effects of a selective D₄ dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. *Arch Gen Psychiat* 54: 567–572
- Mansbach RS, Brooks EW, Sanner MA, Zorn SH (1998): Selective dopamine D₄ receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition. *Psychopharmacology* 135: 194–200
- Merchant KM, Gill GS, Harris DW, Huff RM, Eaton MJ, Lookingland K, Lutzke BS, McCall RB, Piercey MF, Schreur PJ, Sethy VH, Smith MW, Svensson KA, Tang AH, Vonvoigtlander PF, Tenbrink RE (1996): Pharmacological characterization of U-101387, a dopamine D₄ receptor selective antagonist. *J Pharmacol Exp Ther* 279:1392–1403
- Millan MJ, Newman-Tancredi A, Brocco M, Gobert A, LeJeune F, Audinot V, Rivet J-M, Schreiber R, Dekeyne A, Spedding M, Nicolas J-P, Peglion J-L (1998): S 18126 ({2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-ylmethyl]indan-2-yl}), a potent, selective, and competitive antagonist at dopamine D₄ receptors: An in vitro and in vivo comparison with L 745, 870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and raclopride. *J Pharmacol Exp Ther* 287: 167–186
- Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998): Dopamine receptors: from structure to function. *Physiol Rev* 78: 189–225
- Neve KA, Neve RL (1997): *The Dopamine Receptors*. Totowa, Humana Press
- Patel S, Freedman S, Chapman KL, Emms F, Fletcher AE, Knowles M, Marwood R, McAllister G, Myers J, Patel S, Curtis N, Kulagowski JJ, Leeson PD, Ridgill M, Graham M, Matheson S, Rathbone D, Watt AP, Bristow LJ, Rupniak NM, Baskin E, Lynch JJ, Ragan CI (1997): Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D₄ receptor. *J Pharmacol Exp Ther* 283:636–647
- Ralph R, Varty GB, Kelly MA, Wang Y-M, Caron MG, Rubinstein M, Grandy DK, Low MJ, Geyer MA (1999): The dopamine D₂, but not D₃ or D₄, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice. *J Neurosci* 19:4627–4633
- Rubinstein M, Phillips TJ, Bunzow JR, Falzone TL, Dziewczapolski G, Zhang G, Fang Y, Larson JL, McDoughall JA, Chester JA, Saez C, Pugsley TA, Gershanik O, Low MJ, Grandy DK (1997): Mice lacking dopamine D₄ receptors are supersensitive to ethanol, cocaine, and methamphetamine. *Cell* 90: 991–1001
- Sams-Dodd F (1998): Effects of dopamine agonists and antagonists on PCP-induced stereotyped behavior and social isolation in the rat social interaction test. *Psychopharmacology* 135:182–193
- Sanner MA, Chappie TA, Dunaiskis AR, Fliri AF, Desai KA, Zorn SH, Jackson ER, Johnson CG, Morrone JM, Seymour PA, Majchrzak MJ, Faraci S, Collins JL, Duignan DB, Di Prete CC, Lee JS, Trozzi A (1998): Synthesis, SAR, and pharmacology of CP-293,019: A potent, selective dopamine D₄ receptor antagonist. *Bioorg Med Chem Lett* 8:725–730
- Seeman P, Corbett R, Van Tol HHM (1997): Atypical neuroleptics have low affinity for dopamine D₂ receptors or are selective for D₄ receptors. *Neuropsychopharmacology* 16: 93–110
- Tallman JF (1998): NGD 94-1: A specific dopamine-4-receptor antagonist. In Goldstein D, Eisenhofer G, McCarthy R (eds), *Catecholamines: Bridging Basic Science with Clinical Medicine*. San Diego, Academic Press, pp 490–492
- Tarazi FI, Baldessarini RJ (1999): Brain dopamine D₄ receptors: Basic and clinical status. *Int J Neuropsychopharmacol* 2:41–58
- Truffinet P, Tamminga CA, Fabre LF, Meltzer HY, Riviere M-E, Papillon-Downey C (1999): Placebo-controlled study of the D₄/5-HT_{2A} antagonist fananserin in the treatment of schizophrenia. *Am J Psychiat* 156:419–425
- Van Tol HH, Bunzow JR, Guan H-C, Sunahara RS, Niznik HB, Civelli O (1991): Cloning of a human dopamine D₄ receptor gene with high affinity for the antipsychotic clozapine. *Nature* 350:614–619
- Waddington JL, O'Boyle KM (1989): Drugs acting on brain dopamine receptors: A conceptual re-evaluation 5 years after the first selective D₁ antagonist. *Pharmacol Ther* 43:1–52
- Waddington JL, Daly SA, Downes RP, Deveney AM, McCauley PG, O'Boyle KM (1995): Behavioral pharmacology of "D-1-like" dopamine receptors: Further subtyping, new pharmacological probes, and interactions with "D-2-like" receptors. *Prog Neuro-Psychopharmacol Biol Psychiat* 19:811–831
- Waddington JL, Deveney AM, Clifford JJ, Tighe O, Croke DT, Sibley DR, Drago J (1998): D₁-like dopamine receptors: Regulation of psychomotor behavior, D₁-like: D₂-like interactions and effects of D_{1A} targeted gene deletion. In Jenner P, Demirdamar R (eds), *Dopamine Receptor Subtypes*. Amsterdam, IOS Press, pp 45–63
- Zorn SH, Jackson E, Johnson C, Lewis J, Fliri A (1997): CP-226,269 is a selective dopamine D₄ receptor agonist. *Soc Neurosci Abstr* 23:685